Cytek Biosciences (CTKB) Return on Capital Employed (2021 - 2026)

Cytek Biosciences (CTKB) has 6 years of Return on Capital Employed data on file, last reported at 11.72% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 587.0% year-over-year to 11.72%; the trailing twelve-month figure through Mar 2026 stood at 11.72% (down 587.0% YoY), and the FY2025 full-year result was 10.03%, down 525.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 11.72%, down from 10.09% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 1.31% in Q1 2022 and bottomed at 11.72% in Q1 2026.
• The 5-year median for Return on Capital Employed is 5.85% (2025), against an average of 4.82%.
• The widest annual swing landed in 2024, when Return on Capital Employed surged 138 bps; it then slumped 587 bps in 2026.
• A 5-year view of Return on Capital Employed shows it stood at 0.39% in 2022, then slumped by 1477 bps to 6.18% in 2023, then gained by 22 bps to 4.8% in 2024, then tumbled by 110 bps to 10.09% in 2025, then declined by 16 bps to 11.72% in 2026.
• The last three Return on Capital Employed figures came in at 11.72% (Q1 2026), 10.09% (Q4 2025), and 7.59% (Q3 2025), per Business Quant data.

Peer Comparison